Evidence map›Paper›PMID 38017548›Full record

ArticleEuropean journal of medical research2023

A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer.

Qiang Su, Yongbei Zhu, Bingxi He, Bin Dai, Wei Mu, Jie Tian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Qiang SuSchool of Engineering Medicine, Beihang University, Beijing, 100191, China.
Yongbei ZhuSchool of Engineering Medicine, Beihang University, Beijing, 100191, China.
Bingxi HeSchool of Engineering Medicine, Beihang University, Beijing, 100191, China.
Bin DaiNeurosurgery department, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
Wei MuSchool of Engineering Medicine, Beihang University, Beijing, 100191, China. weimu@buaa.edu.cn.
Jie TianSchool of Engineering Medicine, Beihang University, Beijing, 100191, China. jie.tian@ia.ac.cn.
Beihang University · CNCapital Medical University · CN

Funding

Fundamental Research Funds for the Central Universities YWF-20-BJ-J-1048Medical and Health Program of China Railway J2023Z608Ministry of Science and Technology of the People's Republic of China 2017YFA0205200National Natural Science Foundation of China 62027901National Natural Science Foundation of China 62176013National Natural Science Foundation of China 81227901National Natural Science Foundation of China 81930053Scientific Research and Cultivation Program of Haidian District HP2022-19-506005Youth Fund of Beijing Shijitan Hospital 2020-q06
6 · The paper itself

Abstract

backgroundumor cells, immune cells and stromal cells jointly modify tumor development and progression. We aim to explore the potential effects of tumor purity on the immune microenvironment, genetic landscape and prognosis in prostate cancer (PCa).

methodsTumor purity of prostate cancer patients was extracted from The cancer genome atlas (TCGA). Immune cellular proportions were calculated by the CIBERSORT. To identify critical modules related to tumor purity, we used weighted gene co-expression network analysis (WGCNA). Using STRING and Cytoscape, protein-protein interaction (PPI) networks were constructed and analyzed. A Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, Disease Ontology (DO), and Gene Set Enrichment Analysis (GSEA) enrichment analysis of identified modules was conducted. To identify the expression of key genes at protein levels, we used the Human Protein Atlas (HPA) platform.

resultsA model of tumor purity score (TPS) was constructed in the gene expression omnibus series (GSE) 116,918 cohort. TCGA cohort served as a validation set and was employed to validate the TPS. TPS model, as an independent prognostic factor of distant metastasis-free survival (DMFS) in PCa. Patients had higher tumor purity and better prognosis in the low-TPS group. Tumor purity was related to the infiltration of mast cells and macrophage cells positively, whereas related to the infiltration of dendritic cells, T cells and B cells negatively in PCa. The nomogram based on TPS, Age, Gleason score and T stage had a good predictive value and could evaluate the prognosis of PCa metastasis. GO and KEGG enrichment analyses showed that hub genes mainly participate in T cell activation and T-helper lymphocytes (TH) differentiation. Hub genes were mainly enriched in primary immunodeficiency disease, according to DO analysis. SLAMF8 was identified as the most critical gene by Cytoscape and HPA analysis.

conclusionsDynamic changes in the immune microenvironment associated with tumor purity could correlate with a poor DMFS of low-purity PCa. The TPS can predict the DMFS of PCa. In addition, prostate cancer metastases may be related to immunosuppression caused by a disorder of the immune microenvironment.

Indexed as

Prostatic NeoplasmsCell DifferentiationGene Expression ProfilingGene OntologyHumansLymphocyte ActivationMaleSignaling Lymphocytic Activation Molecule FamilyTumor MicroenvironmentSignaling Lymphocytic Activation Molecule FamilySLAMF8 protein, humanDistant metastasis-free survivalImmune infiltrationNomogramProstate cancerTumor purity

Identifiers

PMID38017548
PMCPMC10683297
OpenAlexW4389088023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.